Addressing Vincristine Resistance in CTVT: Clinical Challenges and Therapeutic Adaptations

Vincristine sulphate has long been established as the primary chemotherapeutic agent for CTVT, offering high success rates and predictable outcomes. However, a subset of cases presents with recurrence or resistance, posing a significant clinical challenge. These cases require veterinarians to rethink conventional protocols and adopt alternative or adjunctive strategies to achieve disease resolution^1,2. 

Mechanisms Behind Resistance 

The development of resistance to vincristine is closely associated with the overexpression of P-glycoprotein, a membrane-bound transporter protein. This protein actively pumps chemotherapeutic agents out of tumour cells, reducing intracellular drug concentration and thereby diminishing therapeutic efficacy¹. 

This mechanism explains why some tumours fail to respond despite appropriate dosing and treatment duration. Recognizing resistance early is critical to avoid unnecessary prolongation of ineffective therapy. 

Clinical Limitations of Vincristine Therapy 

Despite its effectiveness, vincristine is not without drawbacks. Several adverse effects have been documented, including: 

• Neurotoxicity and paresthesia  

• Constipation and gastrointestinal disturbances  

• Elevated liver enzymes such as AST, ALP, and bilirubin  

• Temporary reduction in semen quality in male dogs^3,4 

Additionally, vincristine requires strict intravenous administration with proper dilution. Accidental extravasation or administration of undiluted drug can lead to severe tissue necrosis or even life-threatening complications¹. These factors necessitate careful handling and monitoring during treatment. 

Strategies to Overcome Resistance 

Combination with Ivermectin 

One promising strategy involves combining vincristine with ivermectin, an antiparasitic agent that interacts with P-glycoprotein. By inhibiting this transporter, ivermectin can enhance intracellular retention of vincristine, thereby improving its therapeutic effect in resistant cases². 

Switching to Alternative Chemotherapy 

In cases where resistance persists, transitioning to alternative chemotherapeutic agents becomes necessary. 

Doxorubicin 

Doxorubicin, a tumour antibiotic, has been effectively used in vincristine-resistant cases. It demonstrates strong anti-tumour activity but is limited by its potential to cause cardiotoxic effects, including arrhythmias and reduced systolic function. 

Cyclophosphamide and Vinblastine 

These agents serve as additional alternatives, though they are generally considered less effective compared to vincristine. Their use is often guided by individual patient response and tolerance. 

Lomustine: An Emerging Alternative 

Among alternative agents, lomustine has shown particularly promising results in resistant CTVT cases. As an alkylating nitrosourea compound, it is capable of crossing the blood-brain barrier and has been successfully used both as a standalone therapy and in combination with prednisolone¹. 

Clinical reports have demonstrated complete remission in certain cases treated with lomustine alone, highlighting its potential as a valuable second-line therapy¹. Its oral administration and minimal side effect profile further enhance its practicality in clinical settings. 

Why Alternative Strategies Are Crucial 

The need for alternative therapeutic approaches arises from multiple factors, including¹: 

• Development of drug resistance  

• Occurrence of adverse effects  

• Variability in patient response  

Relying solely on a single therapeutic agent may not be sufficient in all cases. Therefore, a flexible and adaptive treatment strategy is essential for successful disease management. 

Clinical Takeaway 

For veterinarians, managing vincristine-resistant CTVT requires early recognition, careful monitoring, and timely intervention. Incorporating alternative agents like lomustine or doxorubicin, along with supportive strategies such as ivermectin combination, can significantly improve outcomes. 

Ultimately, the key lies in individualized treatment planning, guided by tumour response and patient tolerance, ensuring that even resistant cases can be effectively managed with the right therapeutic approach.  

Reference 

1. Biswas N, Singh K, Kumar S, Parmar S, Srivastava N, Khan MH. Therapeutics and Management of Persistent Cases of Canine Transmissible Venereal Tumour: An Update. Animal Reproduction Update. 2024 Jul 1;4(2). https://www.researchgate.net/profile/Newton-Biswas/publication/381583366_Therapeutics_and_Management_of_Persistent_Cases_of_Canine_Transmissible_Venereal_Tumour_An_Update/links/667537771846ca33b842ba3a/Therapeutics-and-Management-of-Persistent-Cases-of-Canine-Transmissible-Venereal-Tumour-An-Update.pdf 

2. Sewoyo PS, Kardena IM. Canine transmissible venereal tumor: treatment review and updates.  Rev Electron Vet. 2022; 23(1): 01-07. https://www.researchgate.net/profile/Palagan-Sewoyo/publication/358200686_Canine_Transmissible_Venereal_Tumor_Treatment_Review_and_Updates/links/61f51f24007fb5044720c780/Canine-Transmissible-Venereal-Tumor-Treatment-Review-and-Updates.pdf 

3. Cunha SC, Silva FB, Corgozinho KB, Da Silva KG, Ferreira AM. Adverse effects of chemotherapy in dogs. World's Veterinary Journal. 2017;7(3):74-82. https://cyberleninka.ru/article/n/adverse-effects-of-chemotherapy-in-dogs 
4. Nazer AT, Becha BB, Jayakumar C, Unnikrishnan MP, Devi STST. Haemato-biochemical evaluation of chemotherapy in canine transmissible venereal tumour. Indian J Anim Reprod.  2023; 44(1): 23-27. https://doi.org/10.48165/ijar.2023.44.01.5